nach oben

Erschienen in:

29.09.2021 | Herzinsuffizienz | Zertifizierte Fortbildung

ARNI, SGLT2-Hemmer, Guanylatzyklase- und Myosin-Aktivatoren

Innovationen in der medikamentösen Therapie der Herzinsuffizienz

verfasst von: Dr. med. Amr Abdin, Prof. Dr. med. Michael Böhm

Erschienen in: CardioVasc | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Auszug

Die Behandlung der chronischen Herzinsuffizienz hat durch die neuen Therapieansätze wie ARNI und SGLT2-Inhibitoren zu einer Senkung der Mortalität und der Krankenhausaufnahme bei Patienten mit reduzierter Ejektionsfraktion geführt. In jüngster Zeit wurden weitere potenzielle Behandlungsmechanismen wie die Guanylatzyklase-Stimulatoren und die kardialen Myosin-Aktivatoren erforscht. …

Abdin A et al. Timely and individualized heart failure management: need for implementation into the new guidelines. Clin Res Cardiol. 2021;13;1-9

Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129-200

McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; https://doi.org/10.1093/eurheartj/ehab368

Chioncel O et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:1574-85

McMurray JJ et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004

Solomon SD et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609-20

McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-71

Anker SD et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail. 2020;22(12):2383-92

Solomon SD et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141:352-61

10.

Solomon SD et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:455-62

11.

Cleland JGF et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39:26-35

12.

Böhm M et al. Ejection fraction in heart failure revisited- where does the evidence start? Eur Heart J. 2020;41:2363-5

13.

Zelniker TA et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31-9

14.

McMurray JJV et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008

15.

Packer M et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24

16.

Zannad F et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396:819-29

17.

Docherty KF et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur. Heart J. 2020;41:2379-92

18.

Zannad F et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Reduced trial. Circulation. 2021;143(4):310-21

19.

Petrie MC et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323:1353-68

20.

Anker SD et al. EMPEROR-Reduced Trial Committees and Investigators. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status - Results from the EMPEROR-Reduced Trial. Circulation. 2021;143(4):337-49

21.

Serenelli M et al. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and prevention of adverse outcomes in heart failure trial (DAPA-HF). Eur Heart J. 2020;41:3402-18

22.

McEwan P et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. Eur J Heart Fail. 2020;22:2147-56

23.

Bhatt DL et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129-39

24.

Bhatt DL et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117-28

25.

Stasch JP et al. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123:2263-73

26.

Armstrong PW et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883-93

27.

Teerlink JR et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail. 2020;22:2160-71

28.

Teerlink JR et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384(2):105-16

29.

Ponikowski P et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396:1895-904

30.

Anker SD et al. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: An Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2020;41:2109-17

31.

Böhm M et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 20174;38(15):1132-43

32.

Anker SD et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17:1050-6

33.

Vaduganathan M et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomized controlled trials. Lance.t 2020; 396:121-8

34.

Halliday BP et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019; 393:61-73

Titel: ARNI, SGLT2-Hemmer, Guanylatzyklase- und Myosin-Aktivatoren
Innovationen in der medikamentösen Therapie der Herzinsuffizienz
verfasst von: Dr. med. Amr Abdin
Prof. Dr. med. Michael Böhm
Publikationsdatum: 29.09.2021
Verlag: Springer Medizin
Schlagwort: Herzinsuffizienz
Erschienen in: CardioVasc / Ausgabe 4/2021
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI: https://doi.org/10.1007/s15027-021-3544-y

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Ultradünne Stents auf lange Sicht vorteilhafter als der Klassenprimus

Von Antidiabetika zu Herztherapeutika

Herzinsuffizienz-Leitlinie 2021

Permanentes Vorhofflimmern: Überleben steigt durch AV-Knoten-Ablation plus CRT

Assistenzsysteme bei akuter und chronischer Herzinsuffizienz

Zentraler Pulsdruck: Prognostischer Parameter für Endorganschäden bei Hypertonie